Enanta Pharmaceuticals (NASDAQ: ENTA) revenue
Enanta Pharmaceuticals reported revenue of $65.3m for fiscal 2025, 3.4% less than in fiscal 2024 ($67.6m). Since fiscal 2016 its revenue has fallen by 26.0%, an average decline of 3.3% a year.
Enanta Pharmaceuticals's revenue has fallen for 7 years in a row, and its best year of the last 10 was fiscal 2018. The biggest drop was in fiscal 2020, −40.3%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $65.3m | −3.4% | −$85.3m | −130.7% |
| 2024 | $67.6m | −14.6% | −$121.7m | −179.9% |
| 2023 | $79.2m | −8.1% | −$137.2m | −173.2% |
| 2022 | $86.2m | −11.2% | −$123.8m | −143.7% |
| 2021 | $97.1m | −20.7% | −$109.6m | −112.9% |
| 2020 | $122.5m | −40.3% | −$41.6m | −34.0% |
| 2019 | $205.2m | −0.7% | $36.7m | 17.9% |
| 2018 | $206.6m | +101.0% | $88.3m | 42.7% |
| 2017 | $102.8m | +16.5% | $24.6m | 23.9% |
| 2016 | $88.3m | — | $30.8m | 34.9% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Enanta Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, Enanta Pharmaceuticals ranks 318th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Enanta Pharmaceuticals, −3.4%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 316th | Intellia Therapeutics | $67.7m | 16.9% |
| 317th | Kura Oncology | $67.5m | 25.2% |
| 318th | Enanta Pharmaceuticals | $65.3m | −3.4% |
| 319th | Nuvation Bio | $62.9m | 699.0% |
| 320th | Tango Therapeutics | $62.4m | 48.3% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Enanta Pharmaceuticals
- How much revenue did Enanta Pharmaceuticals make in fiscal 2025?
- Enanta Pharmaceuticals reported revenue of $65.3m for fiscal 2025, compared with $67.6m in fiscal 2024.
- How much has the revenue of Enanta Pharmaceuticals fallen?
- Between fiscal 2016 and fiscal 2025 it went from $88.3m to $65.3m: 26.0% less, an average decline of 3.3% a year.
- What was the best year for revenue at Enanta Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2018, with $206.6m.
- Where does Enanta Pharmaceuticals rank in its sector by revenue?
- It ranks 318th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Enanta Pharmaceuticals come from?
- From the annual report (Form 10-K) that Enanta Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Enanta Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Enanta Pharmaceuticals: the Enanta Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.